Discussion
Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR…
Discussion
Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with…
Discussion
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
Discussion
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
Discussion
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed…
